{"id":"phase-c-eplerenone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Fatigue"},{"rate":"2-3","effect":"Diarrhea"},{"rate":"1-2","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and decreased cardiac fibrosis and remodeling. Unlike non-selective aldosterone antagonists, eplerenone has minimal affinity for other steroid receptors, reducing hormonal side effects.","oneSentence":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:01.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction left ventricular dysfunction"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eplerenone"],"phase":"marketed","status":"active","brandName":"Phase C: Eplerenone","genericName":"Phase C: Eplerenone","companyName":"National Institute of Cardiology, Warsaw, Poland","companyId":"national-institute-of-cardiology-warsaw-poland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss. Used for Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}